1Division of Oncology, Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3Department of Colorectal Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Copyright © 2017 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Characteristic | Synchronousa) (n=27) | Metachronous (n=19) |
---|---|---|
Initial stage | ||
1 | - | - |
2 | - | 6 |
3 | - | 10 |
4 | 27 | 3 |
Location of primary disease | ||
Ascending | 4 | 4 |
Transverse | 2 | - |
Descending | 13 | 9 |
Rectum | 8 | 6 |
Histology (adenocarcinoma) | ||
Well differentiated | 3 | - |
Moderate differentiated | 23 | 18 |
Poor differentiated | 1 | 1 |
Adjuvant chemotherapy | ||
FOLFOX | 1 | 4 |
Capecitabine | - | 6 |
Leucovorin+5-FU | - | 2 |
UFT | - | 3 |
None | - | 4 |
Interval between primary surgery and initial recurrence (wk) | - | 83.9 (27.3-344.3) |
Microsatellite instabilitya) | ||
Microsatellite stable | 24 | 19 |
Microsatellite instable | 1 | - |
Loss of heterozygositya) | 6 | 8 |
Resection | ||
R0 | 24 | 16 |
R1 | 3 | 3 |
Perioperative chemotherapyb) | ||
FOLFOX/XELOX | 23 | 13 |
FOLFIRI | 4 | 4 |
Capecitabine | - | 2 |
Recurrence | ||
Yes | 20 | 14 |
No | 7 | 5 |
Survival | ||
Yes | 20 | 17 |
No | 7 | 2 |
FOLFOX, cetuximab plus 5-fluorouracil, folinic acid, and oxaliplatin; 5-FU, 5-fluorouracil; UFT, tegafur-uracil; XELOX, capecitabine plus oxaliplatin; FOLFIRI, folinic acid, 5-fluorouracil, and irinotecan.
a) Microsatellite status and loss of heterozygosity were not assessed in two patients,
b) Perioperative chemotherapy: chemotherapy with 6 months of surgery (neoadjuvant/pseudoadjuvant).
Characteristic | Synchronous |
Metachronous (n=19) |
---|---|---|
Initial stage | ||
1 | - | - |
2 | - | 6 |
3 | - | 10 |
4 | 27 | 3 |
Location of primary disease | ||
Ascending | 4 | 4 |
Transverse | 2 | - |
Descending | 13 | 9 |
Rectum | 8 | 6 |
Histology (adenocarcinoma) | ||
Well differentiated | 3 | - |
Moderate differentiated | 23 | 18 |
Poor differentiated | 1 | 1 |
Adjuvant chemotherapy | ||
FOLFOX | 1 | 4 |
Capecitabine | - | 6 |
Leucovorin+5-FU | - | 2 |
UFT | - | 3 |
None | - | 4 |
Interval between primary surgery and initial recurrence (wk) | - | 83.9 (27.3-344.3) |
Microsatellite instability |
||
Microsatellite stable | 24 | 19 |
Microsatellite instable | 1 | - |
Loss of heterozygosity |
6 | 8 |
Resection | ||
R0 | 24 | 16 |
R1 | 3 | 3 |
Perioperative chemotherapy |
||
FOLFOX/XELOX | 23 | 13 |
FOLFIRI | 4 | 4 |
Capecitabine | - | 2 |
Recurrence | ||
Yes | 20 | 14 |
No | 7 | 5 |
Survival | ||
Yes | 20 | 17 |
No | 7 | 2 |
Gene | Synchronous (n=27) |
Metachronous (n=19) |
||
---|---|---|---|---|
Primary | Liver | Primary | Liver | |
KRAS | 12 (44.4) | 11 (40.7) | 7 (36.8) | 7 (36.8) |
APC | 7 (25.9) | 8 (29.6) | 4 (21.1) | 4 (21.1) |
STK11 | - | - | 1 (5.3) | 1 (5.3) |
TP53 | 9 (33.3) | 8 (29.6) | 4 (21.1) | 5 (26.3) |
BRAF | 1 (3.7) | 1 (3.7) | 2 (10.5) | 1 (5.3) |
MLH1 | 4 (14.8) | 4 (14.8) | - | - |
AKT1 | 1 (3.7) | 1 (3.7) | - | - |
PIK3CA | 1 (3.7) | 1 (3.7) | 1 (5.3) | 1 (5.3) |
NRAS | 2 (7.4) | 2 (7.4) | - | - |
CTNNB1 | 1 (3.7) | 1 (3.7) | - | - |
FOLFOX, cetuximab plus 5-fluorouracil, folinic acid, and oxaliplatin; 5-FU, 5-fluorouracil; UFT, tegafur-uracil; XELOX, capecitabine plus oxaliplatin; FOLFIRI, folinic acid, 5-fluorouracil, and irinotecan. Microsatellite status and loss of heterozygosity were not assessed in two patients, Perioperative chemotherapy: chemotherapy with 6 months of surgery (neoadjuvant/pseudoadjuvant).
Values are presented as number (%).